troglitazone has been researched along with Thromboembolism in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Plowman, BK | 1 |
| Morreale, AP | 1 |
1 other study available for troglitazone and Thromboembolism
| Article | Year |
|---|---|
Possible troglitazone-warfarin interaction.
Topics: Anticoagulants; Blood Coagulation; Chromans; Diabetes Mellitus; Drug Interactions; Humans; Hypoglyce | 1998 |